ArticleIntegrative cancer therapies
Pharmacodynamics of huaier aqueous extract against papillary thyroid carcinoma in vivo and in vitro.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) is the main type of malignant tumor of the thyroid gland in adults. Huaier, a traditional Chinese medicinal agent, has demonstrated antitumor efficacy across diverse malignant neoplasms. However, the specific impact of huaier in PTC remains insufficiently elucidated. In this study, we explored the function of huaier in PTC. We treated a PTC cell line (TPC-1) with varying concentration gradients of huaier and we observed that huaier effectively inhibited the proliferation of TPC-1 cells with an IC50 of 2.538 mg/ml. Huaier also modulated the cell cycle of the TPC-1 cell line, and induced apoptosis in TPC-1. Huaier treatment inhibited migration and invasion of TPC-1 cells. Further studies showed that in TPC-1 cells, huaier treatment inhibited the expression of the MAPK and HSP27/STAT3/AKT signaling pathway. We subsequently demonstrated in a nude mouse model that huaier treatment inhibited the progression of PTC tumors. In summary, our data suggest that huaier can inhibit the proliferation, migration, and invasion of PTC cells in vitro and the progression of PTC tumors in vivo, and that this effect may be related to the MAPK and HSP27/STAT3/AKT signaling pathway; therefore, huaier extract is expected to be a new direction for the treatment of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.